Newpath Partners

Newpath Partners is a multi-stage life sciences and healthcare venture capital firm based in Boston, MA, founded in 2018 by physician-scientist Thomas J. Cahill, MD, PhD. The firm operates on a company-formation model, partnering with leading academic scientists at the earliest stages — often before a company formally exists — to build biotechnology companies around breakthrough biology platforms, including gene editing, regenerative medicine, genomics, oncology, and transformational therapeutics. Newpath takes significant ownership stakes and typically assumes board seats or close advisory roles. Its second fund, Newpath Partners II, closed in December 2021 at $350 million and targets 8–12 additional biotech companies, drawing on academic partners at institutions including the Broad Institute, Harvard Medical School, Scripps Research Institute, and Columbia University. The firm has partnered with over 15 scientific founders and its portfolio has seen 2 IPOs and 3 acquisitions, including Neumora Therapeutics, Prime Medicine, and Metsera. Founders can contact the firm at info@newpath.partners.